Hypertension Pipeline Outlook Report 2025: DelveInsight Analyzes Key R&D Progressions Powering Next-Generation Therapies

DelveInsight's, "Hypertension Pipeline Insight, 2025" report provides comprehensive insights about 80+ companies and 100+ pipeline drugs in Hypertension pipeline landscape. It covers the Hypertension pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Hypertension pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore the comprehensive insights by DelveInsight and stay ahead in understanding the Hypertension Treatment Landscape @ Hypertension Pipeline Outlook [https://www.delveinsight.com/sample-request/hypertension-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Key Takeaways from the Hypertension Pipeline Report

* Nov. 25, 2025 - The United States has once again received a D+ for preterm birth in the 2025 March of Dimes Report Card, which has evaluated national maternal and infant health since 2009 across metrics such as preterm birth, prenatal care, infant and maternal mortality, and related indicators. The national preterm birth rate remains unchanged at 10.4%, with nearly 380,000 infants born prematurely in 2024-representing one in every ten births. Significant disparities persist, with preterm birth rates among babies born to Black mothers reaching 14.7%, nearly 1.5 times the overall national rate, and babies born to Medicaid-covered mothers experiencing higher prematurity rates than those with private insurance (11.7% versus 9.6%). Additionally, nearly one-quarter of pregnant individuals (24.5%) did not receive first-trimester prenatal care, marking the fourth consecutive year of decline.
* On 19 November 2025, Apollo Therapeutics Ltd conducted a AP13CP02 study is a phase 2, open-label, dose escalation trial to determine how safe and tolerable multiple subcutaneous (SC) injections of APL-9796 are for patients with PH. The study will also assess how effective APL-9796 could be for treating patients with PH and whether the body produces antibodies working against APL-9796.
* On 19 November 2025, Pfizer announced a study is to learn how the study medicine called PF-07868489 is tolerated and acts in healthy adult people and people with pulmonary arterial hypertension (PAH). An investigator- and participant-blind, sponsor-open, placebo-controlled, single ascending dose study to assess the safety, tolerability, and pharmacokinetics (PK) of PF-07868489 in healthy adult participants.
* DelveInsight's Hypertension pipeline report depicts a robust space with 80+ active players working to develop 100+ pipeline therapies for Hypertension treatment.
* The leading Hypertension Companies such as Gossamer Bio, Addpharma Inc., Insmed Incorporated, Alnylam Pharmaceuticals, 35Pharma Inc, Pfizer, Pharmosa Biopharm Inc., Guangzhou Magpie Pharmaceuticals Co., Ltd., Suzhou Sanegene Bio Inc., JW Pharmaceutical and others.
* Promising Hypertension Pipeline Therapies such as Ramipril and hydrochlorothiazide, Liraglutide , Nebivolol, Metoprolol XL, Aliskiren and HCTZ, Bunazosin, Doxazosin, Valsartin, losartan potassium and others.

Discover groundbreaking developments in Hypertension Therapies! Gain in-depth knowledge of key clinical trials, emerging drugs, and market opportunities @ Hypertension Ongoing Clinical Trials Assessment [https://www.delveinsight.com/sample-request/hypertension-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

The Hypertension Pipeline Report provides a disease overview, pipeline scenario, and therapeutic assessment of the key pipeline therapies in this domain. The Hypertension Pipeline Report also highlights the unmet needs with respect to the Hypertension.

Hypertension Overview

Hypertension, commonly known as high blood pressure, is a chronic medical condition characterized by elevated pressure in the arteries, which can lead to serious health complications if left untreated. It is classified into primary hypertension, which has no identifiable cause and often develops gradually over many years, and secondary hypertension, which results from an underlying condition, such as kidney disease or hormonal disorders.

Hypertension Emerging Drugs Profile

* Seralutinib: Gossamer Bio

Seralutinib, developed by Gossamer Bio, is an inhaled medication designed to treat pulmonary arterial hypertension (PAH). It functions as an antagonist of several receptors, including platelet-derived growth factor receptors (PDGFR and PDGFR), colony-stimulating factor 1 receptor (CSF1R), and c-KIT. This multi-target approach aims to mitigate the inflammatory and proliferative pathways that contribute to pulmonary vascular remodeling associated with PAH. Currently, the drug is in the Phase III stage of its development for the treatment of Pulmonary Arterial Hypertension.

* AD-209: Addpharma Inc.

AD-209 is an investigational drug developed by Addpharma Inc., primarily targeting hypertension. It is part of a broader pipeline that includes various innovative medicines aimed at treating multiple conditions, including hyperlipidemia and diabetes. Currently, the drug is in the Phase III stage of its development for the treatment of Hypertension.

* Zilebesiran: Alnylam Therapeutics

Zilebesiran is an investigational RNA interference (RNAi) therapeutic developed by Alnylam Therapeutics, specifically targeting hypertension. It is designed to inhibit the synthesis of angiotensinogen (AGT), a key precursor in the Renin-Angiotensin-Aldosterone System (RAAS), which plays a crucial role in blood pressure regulation. Zilebesiran works by utilizing RNAi technology to selectively reduce the production of AGT in the liver. This reduction leads to decreased levels of angiotensin II, a potent vasoconstrictor that contributes to elevated blood pressure. By lowering AGT synthesis, zilebesiran aims to achieve sustained reductions in blood pressure over time. Currently, the drug is in the Phase II stage of development to treat Hypertension.

* LAM-001: ORPHAI THERAPEUTICS

LAM-001 is an investigational inhaled formulation of sirolimus (also known as rapamycin) developed by OrphAI Therapeutics. It is designed specifically for the treatment of pulmonary hypertension (PH) and bronchiolitis obliterans syndrome (BOS), conditions that can significantly impact lung function and patient quality of life. Currently, the drug is in the Phase II stage of development to treat Pulmonary Hypertension.

* HS135: 35Pharma Inc.

HS135 is an investigational drug developed by 35Pharma Inc., focusing on the treatment of pulmonary hypertension (PH) and related cardiometabolic diseases. It is a multi-specific receptor ectodomain ligand trap designed to neutralize activins and growth differentiation factors (GDFs), which are validated drivers of these conditions. HS135 functions as a ligand trap that specifically targets and inhibits the activity of activins and GDFs, particularly activin A and GDF-8. By doing so, it aims to rebalance the signaling pathways involved in various pathologies associated with pulmonary hypertension and obesity-related heart failure. Currently, the drug is in the Phase I stage of development to treat Pulmonary Arterial Hypertension.

Stay informed about the Hypertension pipeline trends! Uncover critical updates on therapeutic innovations and their potential impact on patients and the healthcare industry @ Hypertension Unmet Needs [https://www.delveinsight.com/sample-request/hypertension-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

The Hypertension Pipeline Report Provides Insights into

* The report provides detailed insights about companies that are developing therapies for the treatment of Hypertension with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Hypertension Treatment.
* Hypertension Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Hypertension Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Hypertension market

Hypertension Companies

Gossamer Bio, Addpharma Inc., Insmed Incorporated, Alnylam Pharmaceuticals, 35Pharma Inc, Pfizer, Pharmosa Biopharm Inc., Guangzhou Magpie Pharmaceuticals Co., Ltd., Suzhou Sanegene Bio Inc., JW Pharmaceutical and others.

Hypertension pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

* Oral
* Intravenous
* Subcutaneous
* Parenteral
* Topical

Hypertension Products have been categorized under various Molecule types such as

* Recombinant fusion proteins
* Small molecule
* Monoclonal antibody
* Peptide
* Polymer
* Gene therapy

Transform your understanding of the Hypertension Pipeline! See the latest progress in drug development and clinical research @ Hypertension Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/hypertension-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Scope of the Hypertension Pipeline Report

* Coverage- Global
* Hypertension Companies- Gossamer Bio, Addpharma Inc., Insmed Incorporated, Alnylam Pharmaceuticals, 35Pharma Inc, Pfizer, Pharmosa Biopharm Inc., Guangzhou Magpie Pharmaceuticals Co., Ltd., Suzhou Sanegene Bio Inc., JW Pharmaceutical and others.
* Hypertension Pipeline Therapies- Ramipril and hydrochlorothiazide, Liraglutide, Nebivolol, Metoprolol XL, Aliskiren and HCTZ, Bunazosin, Doxazosin, Valsartin, losartan potassium and others.
* Hypertension Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Hypertension Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Stay Ahead in Cardiovascular Diseases Research-Access the Full Hypertension Pipeline Analysis Today! @ Hypertension Drugs and Companies [https://www.delveinsight.com/sample-request/hypertension-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Table of Contents

* Introduction
* Executive Summary
* Hypertension: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Hypertension - DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* Seralutinib: Gossamer Bio
* Mid Stage Products (Phase II)
* Zilebesiran: Alnylam Therapeutics
* Early Stage Products (Phase I)
* HS135: 35Pharma Inc.
* Preclinical and Discovery Stage Products
* Drug name: Company name
* Inactive Products
* Hypertension Key Companies
* Hypertension Key Products
* Hypertension- Unmet Needs
* Hypertension- Market Drivers and Barriers
* Hypertension- Future Perspectives and Conclusion
* Hypertension Analyst Views
* Hypertension Key Companies
* Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=hypertension-pipeline-outlook-report-2025-delveinsight-analyzes-key-rd-progressions-powering-nextgeneration-therapies]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.